Vemurafenib and trametinib were purchased from Selleck chemicals (Houston, TX) and the pan-PI3K inhibitor (PI3Ki) GSK2126458 was obtained from GlaxoSmithKline (GSK, PA) under a material transfer agreement. Interferon γ (INFγ) was obtained from Sigma Aldrich (St Louis, MO). Human melanoma cell lines (M series) were established from patient's biopsies under UCLA IRB 11-003254 as previously described (16 (link)). WM1366 and SBCL2 were obtained from the American Type Culture Collection (ATCC, Rockville, MD). Growing media, maintenance and mycoplasma testing of the cell lines were as described before (16 (link)). BRAF mutant cell lines with the in vitro acquired Vemurafenib resistance are indicated by the AR suffixes. Except M249AR4 that contains a secondary NRAS mutation, the rest of acquired resistant cell lines were maintained in the growing media containing 1µM of Vemurafenib.
Interferon γ infγ
Manufactured by Merck Group
Sourced in United States
Interferon γ (INFγ) is a cytokine that plays a crucial role in the immune system. It is produced primarily by natural killer cells and certain types of T cells. INFγ functions to activate various immune cells, including macrophages, natural killer cells, and T cells, enhancing their ability to respond to and eliminate pathogens. It also has a role in regulating the expression of certain genes involved in immune responses.
Automatically generated - may contain errors
Lab products found in correlation
Trametinib, by Selleck Chemicals (1 mentions)
Vemurafenib, by Selleck Chemicals (1 mentions)
Wm1366, by American Type Culture Collection (1 mentions)
Sbcl2, by American Type Culture Collection (1 mentions)
Inf γ, by Merck Group (1 mentions)
Lipopolysaccharides (lps), by Merck Group (1 mentions)
Accutase solution, by Merck Group (1 mentions)
2 protocols using interferon γ infγ
1
Melanoma Acquired Resistance Protocol
2
Macrophage-MSC Co-culture Activation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Four days after starting differentiation of CD14+ PBMCs to MΦ, cells were detached using Accutase® solution (Sigma-Aldrich, St. Louis, MO, USA). 2 × 105 cells were added to the same amount of BM-hMSCs seeded into nunclon® Δ 6-well plates (Thermo Fisher Scientific, Waltham, MA, USA) the day before. Simultaneously, macrophages were activated using lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis, MO, USA) and interferon-γ (INF-γ) (Sigma-Aldrich, St. Louis, MO, USA), which was added to the hMSC cultivation medium (10 ng/mL LPS and 20 ng/mL INF- γ) [31 (link)].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!